An Open-label, Multicenter, Single-arm, Phase 1b/2 Study of NANT-008 in Combination With 5-fluorouracil, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma.
Phase of Trial: Phase I/II
Latest Information Update: 15 Aug 2018
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors NantPharma
- 21 May 2018 Status changed from not yet recruiting to recruiting.
- 28 Apr 2017 New trial record